Last month, the COVID figures stabilized, and then rebounded on a dangerous trajectory, which shows that we are still far behind. Experts say that the increase in the number of cases in the United States may be due to two reasons: relaxation of restrictions, and the emergence of more contagious new variants from the United Kingdom, Brazil and South Africa. These strains have added unpredictable new factors to the pandemic, and many medical professionals warn that the pandemic may hinder our efforts to achieve cattle immunity.
However, there are many reasons to be cautiously optimistic about the future of the pandemic, among which vaccines are the main factor. With three highly effective lenses on the market, we can now resist these new COVID variants by slowing their spread.Although there are currently any vaccines may In order to effectively respond to emerging variants, only one company has formally evaluated its products and found that it can effectively respond to these new threats. Read on to find out which vaccine to test, and for more major vaccine news, check out Pfizer’s vaccines that can protect you at least in the long term.
Read related original articles Best life.
A team of researchers from Pfizer and the University of Texas Medical Branch set out to answer the following question: whether the vaccine developed against older COVID variants can resist the new strain.And finally publish the results to New England Journal of Medicine, They set up a laboratory test to test antibodies in the serum samples of 15 volunteers who received two vaccine doses. In this small sample, they found that the vaccine produced a “large” antibody response to the laboratory-designed virus variant.
Taken together, these findings suggest that this vaccine may be effective against the variants studied, although to be precise, their effectiveness in the real world will require data about the actual effect of the vaccine in the population, not just Laboratory research like this. ,”report BBC Science Focus. They explained that further research might look at other aspects of the immune response, including T cell (cellular) immunity. To get more health news sent directly to your inbox, please sign up for our daily newsletter.
Pfizer seems to be able to resist all new variants, but research has found that Pfizer does do this to varying degrees depending on the type of variant. The research team found that the bullet has the most protective effect on the original strain. The B117 variant was first discovered in the UK, while the response to the P1 variant from Brazil was slightly lower. The Pfizer vaccine was found to have the least resistance to the B151 variant first discovered in South Africa.
“It can be assured that although the levels of the P1 and B151 variants are low, they are still high, which may well indicate that the vaccine will be effective,” Peter EnglishInfectious Disease Control Consultant MD told Scientific focus. According to the study, for more information about the performance of Pfizer lenses, please see “Pfizer vaccine is 100% effective for this age group.”
As reported by Reuters, Pfizer announced on April 1 that it would update its trial data in Phase 3 and now believe that their two-dose vaccine has an effective rate of 91%, and the total work efficiency is slightly lower than previously announced.
Other data come from 12,000 individuals who have been vaccinated for at least six months, and “a small number of research volunteers in South Africa”, where the B151 variant is common. On the surface, this seems to have compromised the results of the initial 44,000 voluntary trials, but this news actually confirms that Pfizer vaccines provide effective protection in an increasingly complex pandemic environment.
Although the current Pfizer vaccine seems to provide important protection against COVID variants, the company reiterated this week that they still expect to require both an intensified injection and an upgraded vaccine.
On February 25, the pharmaceutical company announced that they will begin evaluating booster injections related to the new variant. “Our aggressive clinical development strategy aims to lay the foundation for today, which will enable us to meet the challenges of tomorrow. We want to be prepared for different situations,” Ugur Sahin, The CEO and co-founder of BioNTech said in the announcement. He added: “Therefore, we will evaluate the second boost of immunity in the current plan and prepare for the possible rapid adaptability of the vaccine to deal with new variants that may escape the current mRNA-based vaccine version.” About Pfizer For more information on the efficacy of the vaccine, please see If you have this common condition, the Pfizer vaccine may not be effective.